152 related articles for article (PubMed ID: 38000881)
1. Adding new childhood vaccines to China's National Immunization Program: evidence, benefits, and priorities.
Zhang H; Lai X; Patenaude BN; Jit M; Fang H
Lancet Public Health; 2023 Dec; 8(12):e1016-e1024. PubMed ID: 38000881
[TBL] [Abstract][Full Text] [Related]
2. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
3. National and provincial impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in China: a modeling analysis.
Zhang H; Garcia C; Yu W; Knoll MD; Lai X; Xu T; Jing R; Qin Y; Yin Z; Wahl B; Fang H
BMC Med; 2021 Aug; 19(1):181. PubMed ID: 34376214
[TBL] [Abstract][Full Text] [Related]
4. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination.
Clark A; Jauregui B; Griffiths U; Janusz CB; Bolaños-Sierra B; Hajjeh R; Andrus JK; Sanderson C
Vaccine; 2013 Jul; 31 Suppl 3():C19-29. PubMed ID: 23777686
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with recommendation behaviors of four non-National Immunization Program vaccines: a cross-sectional survey among public health workers in China.
Lyu Y; Lai X; Ma Y; Fang H
Infect Dis Poverty; 2023 Oct; 12(1):91. PubMed ID: 37805654
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
8. Advancing the National Immunization Program in an era of achieving universal vaccine coverage in China and beyond.
Chen S; Rodewald LE; Du AH; Tang S
Infect Dis Poverty; 2024 Mar; 13(1):25. PubMed ID: 38475849
[TBL] [Abstract][Full Text] [Related]
9. Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis.
Lai X; Garcia C; Wu D; Knoll MD; Zhang H; Xu T; Jing R; Yin Z; Wahl B; Fang H
Lancet Reg Health West Pac; 2023 Mar; 32():100666. PubMed ID: 36785861
[TBL] [Abstract][Full Text] [Related]
10. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.
Chen S; Gao S; Li J; Li J; Duan ZJ
Vaccine; 2023 Jan; 41(2):547-554. PubMed ID: 36503856
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
14. Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs.
Wang J; Zhang H; Zhang H; Fang H
Hum Vaccin Immunother; 2022 Dec; 18(7):2090162. PubMed ID: 35816415
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Lagoubi Y; Sfar MT; Gomez JA
Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
18. Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India.
Ghia C; Wasserman M; Fletcher M; Farkouh R; Rambhad G
Value Health Reg Issues; 2018 May; 15():99-105. PubMed ID: 29655052
[TBL] [Abstract][Full Text] [Related]
19. Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
Marijam A; Schuerman L; Izurieta P; Pereira P; Van Oorschot D; Mehta S; Ota MO; Standaert B
Hum Vaccin Immunother; 2022 Dec; 18(7):2135916. PubMed ID: 36507685
[TBL] [Abstract][Full Text] [Related]
20. 13-Valent pneumococcal conjugate vaccines vaccination innovative strategy in Weifang City, China: a case study.
Wang J; Wang Y; Xu R; Zhang T; Jiang Y; Wang Y; Wang Y; Du Y; Sun W; Deng K; Yang W; Wang Z; Feng L; Wang C
Infect Dis Poverty; 2023 Dec; 12(1):110. PubMed ID: 38037092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
